The most successful method to date uses the N-acetylgalactosamine (GalNAc) ligand which, when conjugated to RNA moieties, allows cellular uptake, but only into liver hepatocytes. A few RNA ...

Researchers are also seeking other GalNAc-like modifications that might act as effective address labels for other tissues in the body. Pricing is another hurdle. Many current RNA drugs are priced ...

Wave added that it plans to highlight the WVE-006 data along with data from its GalNAc-RNA editing programs and preclinical data for its obesity drug candidate WVE-007 during its Annual Research ...

Updates included new preclinical data for Wave’s GalNAc-small interfering RNA (siRNA) approach for obesity, WVE-007, which is on track to initiate a clinical trial in the first quarter of 2025.

Oct 30 (Reuters) - WAVE Life Sciences Ltd: * WAVE LIFE SCIENCES LTD: PLANS TO HAVE FIVE GALNAC-RNA EDITING OR GALNAC-SIRNA PROGRAMS IN CLINIC BY 2026 * WAVE LIFE SCIENCES LTD: WVE-007 (INHBE ...

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs ...